Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2014 by Dana-Farber Cancer Institute.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Brigham and Women's Hospital
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Northwestern University
University of Virginia
Genentech, Inc.
Novartis
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber/Brigham and Women's Cancer Center
ClinicalTrials.gov Identifier:
NCT00859222
First received: March 9, 2009
Last updated: June 30, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2014
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):